MetaCap

Absci (ABSI) vs iSpecimen (ISPC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Absci is the larger company by market cap ($1.30 billion vs $2.6 million), about 491.1 times the size. iSpecimen converts more of its revenue into profit, with a net margin of -543.7% versus -4113.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABSI-18.55%ISPC-58.52%
+36%-14%-63%
Oct 7, 20261 yearNov 20, 2026
ABSI-26.08%ISPC-59.62%
+13%-25%-63%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABSI versus ISPC key metrics
MetricABSIISPC
Share price$7.51$0.4563
Market cap$1.30B$2.64M
1-day change-7.97%-13.58%
YTD return+115.19%—
1-year return+156.31%—
5-year return-31.79%—
EPS (TTM)$-0.79$-52.98
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.80M$1.93M
Revenue growth (YoY)-38.24%-79.24%
Net income (latest FY)$-115.18M$-10.49M
Gross margin—11.18%
Operating margin-4297.04%-465.42%
Net margin-4113.68%-543.68%
52-week high$12.55$27.44
52-week low$2.24$0.432
Distance from 52-week high-40.14%-98.34%
Analyst consensusstrong_buy—
Avg. price target upside+100.93%—
Average volume4.08M598.66K
Shares outstanding172.75M5.79M
Employees1407
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Absci is about 491.1 times larger than iSpecimen by market value ($1.30B vs $2.64M).
  • iSpecimen is more profitable, keeping -543.7 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
  • Absci grew revenue faster in its latest fiscal year (-38.24% vs -79.24%).

About Absci

ABSI stock →

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees

About iSpecimen

ISPC stock →

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees

ABSI vs ISPC FAQ

Which is bigger, Absci or iSpecimen?

Absci (ABSI) is larger, with a market capitalization of $1.30B compared with $2.64M for iSpecimen (ISPC).

Are Absci and iSpecimen in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons